Regeneron's trevogrumab preserves 70% of muscle loss in obesity trials
Regeneron's trevogrumab prevents 70% of muscle loss in obesity patients treated with semaglutide, per Phase 2 COURAGE trial results.
GLP-1 receptor agonists
Latest GLP-1 receptor agonists coverage.